Verici Dx plc (LON:VRCI – Get Free Report) shares rose 5.7% during mid-day trading on Thursday . The company traded as high as GBX 0.40 and last traded at GBX 0.37. 308,972 shares changed hands during mid-day trading, a decline of 81% from the average session volume of 1,586,309 shares. The stock had previously closed at GBX 0.35.
Verici Dx Stock Performance
The company has a current ratio of 3.94, a quick ratio of 8.49 and a debt-to-equity ratio of 3.03. The firm’s fifty day moving average price is GBX 0.38 and its 200-day moving average price is GBX 0.51. The firm has a market cap of £8.96 million, a price-to-earnings ratio of -0.33 and a beta of 1.26.
Verici Dx Company Profile
Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage.
Recommended Stories
- Five stocks we like better than Verici Dx
- MarketBeat Week in Review – 07/20- 07/24
- AMD and Cerbras Create A New Blueprint For Hardware
- Intel Earnings Reveal Whether the Chip Selloff Created a Buy
- CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test
Receive News & Ratings for Verici Dx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verici Dx and related companies with MarketBeat.com's FREE daily email newsletter.
